Category: Uncategorized

xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »

xCures Joins Big Names in Aetion’s New Initiative

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Aetion’s initiative will focus on better… Read more »

Finally, cancer patients have real-time access to their medical records

Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries. EINPressWire, 11/8/22 Last month, the 21st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format. In… Read more »

xCures and mProbe partner to help cancer patients determine optimal treatments

xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to… Read more »

xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol. xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse… Read more »